GSTP 1 GSTP GSTP 1 c.313A>G, XPD XPD XPD c.934G>A, XPF XPF XPF c.2505T>C and CASP 9 CASP CASP 9 c.‐1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation

摘要

Abstract Cisplatin ( CDDP ) chemotherapy associated with radiation ( RT ) has been used in advanced head and neck squamous cell carcinoma ( HNSCC ) patients, and vomiting is a common side effect during treatment. This prospective study aimed to identify the roles of GSTM 1 and GSTT 1 (presents or nulls), GSTP 1 c.313AG, XPC c.2815AC, XPD c.934GA and c.2251AC, XPF c.2505TC, ERCC 1 c.354CT, MLH 1 c.?93GA, MSH 2 c.211 + 9CG, MSH 3 c.3133GA, EXO 1 c.1765GA, TP 53 c.215GC, CASP 3 c.‐1191AG and c.‐1168GT, CASP 9 c.‐1339AG, CASP 8 c.‐937_‐932del AGTAAG , FAS c.‐1378GA and c.‐671AG, and FASL c.‐157‐687CT single nucleotide polymorphisms, involved in CDDP metabolism, in vomiting severity in 88 HNSCC patients treated with CDDP and RT . Ondansetron and dexamethasone were administered as anti‐emetic therapy. Patients with GSTP 1 c.313 AG or GG genotype alone and combined with XPD c.934 GA or AA , XPF c.2505 TC or CC , and CASP 9 c.‐1339 AG or GG genotypes had 4.28, 5.00, 5.45 and 5.38 more chances of presenting moderate/severe vomiting than patients with others genotypes. Our data suggest, for the first time, that inherited abnormality in apoptosis pathway alone or combined with inherited abnormalities in DNA repair pathway, is capable of modulating emesis in HNSCC patients under CDDP chemoradiation and may be used for selecting patients who should receive pre‐emptive anti‐emetic therapy.